Results 31 to 40 of about 29,580 (292)
Pediatric Rheumatology Online Journal, 2021 Background This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH). Methods Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between ...
Ying Chi +5 more
doaj +1 more source
Клиническая онкогематология, 2021 Aim. To comparatively analyze myelofibrosis treatment outcomes with the use of ruxolitinib versus ruxolitinib with subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as to assess the efficacy of ruxolitinib in pre- and post-
Mariya Vladimirovna Barabanshchikova +11 more
doaj +1 more source
Alopecia areata: a multifactorial autoimmune condition [PDF]
, 2019 Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P. +3 more
core +1 more source
TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis [PDF]
, 2015 Pancreatic ductal adenocarcinomas (PDACs) overexpress pro-angiogenic factors but are not viewed as vascular. Using data from The Cancer Genome Atlas we demonstrate that a subset of PDACs exhibits a strong pro-angiogenic signature that includes 37 genes ...
Cheng, Monica +8 more
core +5 more sources
CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. [PDF]
, 2019 Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a genetically heterogeneous subtype of B-cell ALL characterized by chromosomal rearrangements and mutations that result in aberrant cytokine receptor and kinase signaling.
Delgado-Martin, Cristina +5 more
core +2 more sources
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Case Reports in Oncological Medicine, 2020 Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to ...
Philip T. Sobash +2 more
doaj +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
Ruthenium Complexes in Protein Science: Heading a New Generation of Therapeutic and Analytical Tools
Angewandte Chemie, EarlyView.This review presents the latest advances in the development of ruthenium complexes within the field of protein science, highlighting their potential applications in biomedical and bioanalytical fields. Abstract Ruthenium complexes are distinguished by their versatile coordination chemistry, redox behaviors and photochemical properties. In recent years,
Liyan Zhang, Yun Chen, Sylvestre Bonnet
wiley +2 more sources
Understanding Cardiovascular Events With JAK Inhibitors: Similarities and Differences of the Vascular Effects Between Different JAK Inhibitors on Endothelial Cells Exposed to Inflammatory Cytokines. [PDF]
ACR Open RheumatolObjective A cardiovascular safety issue has been associated with JAK inhibitors (JAKi). This study compares the effects of distinct approved JAKi on endothelial cell (EC) dysfunction and apoptosis during inflammation. Methods Massive inflammation was induced in human vascular ECs by tumor necrosis factor (TNF) with interleukin‐17A (IL‐17A) treated or ...
Zavoriti A, Miossec P.
europepmc +2 more sources
Frontiers in Pharmacology, 2021 Background: Chronic active Epstein-Barr virus (CAEBV) infection is one of the EBV-positive T- or NK-cell lymphoproliferative diseases. There is no safe and effective treatment currently and the only proven curable therapy is allogeneic hematopoietic stem
Yue Song +3 more
doaj +1 more source